SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company based in New York City, focuses on developing immunotherapeutics like galinpepimut-S and GFH009 for various cancer types. Founded in 2008, the company employs 17 people and targets cancer with treatments licensed from institutions like Memorial Sloan Kettering Cancer Center and GenFleet Therapeutics.
SELLAS Life Sciences Group (SLS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, SELLAS Life Sciences Group's actual EPS was -$0.13, beating the estimate of -$0.17 per share, resulting in a 22.02% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
